Omix Ocas

GL Pharm Tech Corporation · Phase 1 active Small molecule

At a glance

Generic name	Omix Ocas
Also known as	Tamsulosin
Sponsor	GL Pharm Tech Corporation
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A PK Study GL2702 GLARS-NF1 and Omix Ocas® in Healthy Male Volunteers (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Omix Ocas CI brief — competitive landscape report
Omix Ocas updates RSS · CI watch RSS
GL Pharm Tech Corporation portfolio CI